Questions like these can provide a very good estimate of how prevalent a condition may be and what other conditions or exposures may be associated with a positive response.

MCS was first described by Theron Randolph in 1959, and since then has been defined with a variety of similar but inconsistent criteria for both clinical practice and research purposes. In 2025, the Marilyn Brachman Hoffman Foundation issued our first competitive request for applications.